GlassScriptPhysician profile
Anton Sabiev
NPI 1871042440
$1,225.59
in general payments reported to CMS, 2019-2025
11 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $285 · 2023: $381 · 2024: $427 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $684.46 | 2023-2025 | Blastx, Xperience, Surgx |
| Organogenesis INC. | $166.22 | 2023-2024 | Nushield, Affinity, Puraply Wound Matrix |
| Smith+Nephew, INC. | $90.17 | 2023 | Collagenase Santyl, Regranex |
| Daiichi Sankyo INC. | $75.02 | 2022 | |
| Urovant Sciences INC | $72.44 | 2022 | |
| Antares Pharma, INC. | $44.88 | 2022 | |
| Scynexis, INC. | $24.62 | 2022 | |
| Genzyme Corporation | $20.11 | 2022 | |
| Acerus Pharmaceuticals Corporation | $17.40 | 2022 | |
| Evofem Biosciences, INC. | $15.62 | 2022 | |
| Agile Therapeutics, INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Sabiev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.